OncoDaily

Ki67 May Replace Traditional Grading Methods in Lung NETs - Thor Halfdanarson @OncoThor oncodaily.com/voices/thor-ha…

New Study Suggests Survival Benefit With GLP-1 RAs in Endometrial Cancer - GILBERTO de lima LOPES Junior @GlopesMd oncodaily.com/voices/gilbert…

The Babak Lab - FDA Approves Datroway for Metastatic Triple-Negative Breast Cancer @Babaklab @US_FDA oncodaily.com/voices/the-bab…

Key Lower GI Studies to Watch at ASCO26 - Rutika Mehta @rutikamehtaMD oncodaily.com/voices/rutika-…

@HemeOncBuddy We would like to inform you that your post has been published on OncoDaily. Thank you for sharing! oncodaily.com/voices/veli-ba…

🫁 #ASCO2026 LUNG CANCER ➡️ full trial summaries The practice-moving 1️⃣Early-stage NSCLC, 2️⃣SCLC, 3️⃣Surgery & MRD abstracts 4️⃣Other categorized ➡️ design, endpoints, results, safety, and the bottom line for each. 🧵👇 #ASCO26 #LCSM oncologist on the day when ASCO released abstracts:

ASCO26 to Feature Practice-Changing Breast Cancer Updates, and Innovation From China - Paolo Tarantino @PTarantinoMD oncodaily.com/voices/paolo-t…

🫁 DESTINY-Lung03 gives a very clear message in HER2-overexpressing NSCLC: T-DXd remains active, but adding more treatment was not better. In Part 1 of the open-label, multicenter phase 1b DESTINY-Lung03 trial, Planchard, Kim, Suksombooncharoen et al. evaluated trastuzumab deruxtecan (T-DXd)-based regimens in previously treated metastatic HER2-overexpressing NSCLC. The study tested: 🔹 T-DXd + durvalumab + cisplatin 🔹 T-DXd + durvalumab + carboplatin 🔹 T-DXd monotherapy 5.4 mg/kg The monotherapy arm showed the cleanest clinical signal: 📌 Confirmed ORR: 44.4% 📌 Median DoR: 11.0 months 📌 Median PFS: 8.2 months 📌 Median OS: 17.1 months 📌 Adjudicated drug-related ILD/pneumonitis: 5.6%, both grade 2 Exploratory subgroup data were also notable: 📌 HER2 IHC 3+ ORR: 56.3% 📌 HER2 IHC 2+ ORR: 35.0% 📌 Prior EGFR TKI exposure ORR: 68.4% But the triplet combinations told a different story. Both platinum-containing regimens had substantial toxicity, including dose-limiting toxicities and fatal drug-related adverse events. The data did not support further development of T-DXd + durvalumab + platinum chemotherapy in this previously treated population. The key takeaway: HER2 overexpression is an actionable biomarker in NSCLC, and T-DXd monotherapy continues to show meaningful activity. But DESTINY-Lung03 also reminds us that precision oncology is not about adding more drugs, it is about finding the right therapeutic window. This study supports broader attention to HER2 IHC testing in NSCLC and reinforces the need for lung cancer-specific HER2 testing standards. oncodaily.com/oncolibrary/lu… @dplanchard @stephanieplsaw @erica_nakajima #DESTINYLung03

🎀 Breast cancer cure rates have changed dramatically, but the most important message is still simple: Stage at diagnosis matters. When breast cancer is found early, cure is possible for many patients. According to SEER data, localized breast cancer has a 5-year relative survival rate above 99%, while regional disease has a survival rate of about 87%. Once breast cancer becomes metastatic, the 5-year relative survival rate falls to around 32%. That gap tells the whole story. 🔎 Early detection saves lives. 🧬 Biology matters. 🎯 Personalized treatment changes outcomes. 🤝 Equity determines who truly benefits from progress. Today, breast cancer is no longer treated as one disease. HR+/HER2-negative, HER2-positive, and triple-negative breast cancers each behave differently and require different treatment strategies. 💗 HER2-positive breast cancer is one of oncology’s biggest success stories, transformed by targeted therapy. ⚡ Triple-negative breast cancer remains one of the greatest challenges, but early-stage disease can still be cured in many patients with modern multimodal treatment. 🌿 Hormone receptor-positive breast cancer often has excellent outcomes, but late recurrence remains an important long-term concern. The future of breast cancer care is not only about increasing survival. It is about: 🩺 finding disease earlier 💊 treating smarter 🛡️ reducing unnecessary toxicity 🌍 improving access to care 🎗️ supporting long-term survivorship Breast cancer cure rate is improving, but progress must be measured not only by statistics, but also by quality of life, equity, and the number of patients who get to live beyond cancer. 📖 Read the full article on OncoDaily. oncodaily.com/oncolibrary/br…

@VincentRK We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/vincent…

Most important #ASCO26 myeloma abstract. Practice changing. Majestec-9 trial. PFS significantly better with Teclistmaab vs PVd/Kd (HR, 0.29; 95% CI, 0.23–0.38; P<0.0001); 18-mo PFS rate: 69.8% vs 26.9%. OS significantly better with Tec vs PVd/Kd (HR, 0.60; 95% CI, 0.43–0.83; P=0.002) Based on this, teclistamab now becomes the leading first choice along with ciltacel for relapsed myeloma in dara refractory patients. asco.org/abstracts-pres…

@PaulJiL @ASCO We would like to inform you that your post has been published on OncoDaily. Thank you for sharing! oncodaily.com/voices/pablo-j…

#ASCO26 Eager to review the Ph2 #KEYCHAIN presentation about patients with unfavorable-risk p16+ HNSCC Thought-provoking trial in this difficult space to reach a H&N PACIFIC/ADRIATIC protocol as in lung. Unlike KN412, pembro is replacing cis, not added to CRT Radical RT+pembro vs RT+Cis 📈2yPFS: 84vs70%; HR 0.57 (0.25-1.31) p=0.09 🟢 📈2yOS: 98vs85%; HR 0.33 (0.09-1.28) p=0.048🟢 ⚠️lenient 1-side α=0.15 June 1. HallD1. 4:30. @drlorenmell #hncsm @OncoAlert @brunolarvol

ASCO26 Highlights Growing Evidence Around GLP-1 Agonists and Cancer Outcomes - Nina Niu Sanford @NiuSanford @WSJ oncodaily.com/voices/nina-ni…

@OncoThor We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/thor-ha…

Are we finally going to move from counting mitoses and assessing necrosis when assigning tumor grade in lung NETs...? Ki67, is your time finally here...? And can we please kill the "carcinoid" as a diagnostic term while we make the move to Ki67 for grading...? link.springer.com/article/10.100…

@DrCatharineY We would like to inform you that your post has been published on OncoDaily. Thank you for sharing! oncodaily.com/voices/cathari…

A reminder that GLP-1 drugs trace back to decades of NIH-supported basic science, especially diabetes/endocrinology research. This is why we fund basic research.

@NiuSanford @OncoAlert We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/nina-ni…

This WSJ article getting much attention but all studies observational. Though signal appears to be consistent & ~42 (!!) #ASCO26 abstracts also reporting association b/w GLP-1 & better cancer outcomes. Hope for RCTs to clarify true anticancer biology vs. confounding. @OncoAlert

@IASLC We would like to inform you that your post has been published on OncoDaily. Thank you for sharing! oncodaily.com/voices/iaslc-5…

New microlearning + printable resource for thoracic oncology care teams now available! This quick guide supports early recognition and management of cytokine release syndrome (CRS) associated with BiTE therapies in lung cancer treatment. Includes symptoms, management considerations & a practical patient care workflow. Access the resource: bit.ly/4tzGxXT Nurses & allied health professionals: help shape future IASLC resources by taking the NAHP survey: bit.ly/48StXvh #ThoracicOncology #LungCancer #OncologyNursing

Optimizing Venetoclax Duration in AML - Talha Badar @TalhaBadarMD oncodaily.com/voices/talha-b…

GLP-1 Agonists May Reduce Mortality Risk in HR+/HER2− mBC - Gilberto Lopes and Harold Burstein @DrHBurstein @GlopesMd oncodaily.com/voices/gilbert…

@TalhaBadarMD We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/talha-b…

#weekend_review #AML #leusm 🧵 Optimizing Venetoclax Duration in AML (Ven + HMA) Key observations from available data: 🔹 VIALE-A established efficacy (CR/CRi 66%, median OS 14.7 mo), not necessarily the ideal duration for every patient; Persistent cytopenias and infectious complications remain major barriers to prolonged exposure. 🔹 Karrar et al. (Mayo) suggest shorter durations (14 vs 21 vs 28 days) may be feasible in selected patients, but shorter duration should NOT be assumed to be intrinsically less myelosuppressive (AJH) 🔹 Prospective evidence does NOT currently support routine universal 7–14 day induction Venetoclax. 🔹 7+7 French study showed comparable response after 2nd cycle but toxicity was similar to 28 day venetoclax. 🔹 FILO data raise an important concept: treatment-free remission may be feasible after prolonged MRD-negative remission in favorable-risk disease (ELN2024), highlighting the importance of biology rather than fixed duration. 🔹 Metronomic/weekly Dec+Ven approaches and ongoing randomized studies (Opti-AML/Beat AML) may further redefine exposure strategies. Current practice increasingly individualizes Venetoclax duration based on: ✓ Age/frailty ✓ Comorbidities ✓ Molecular profile/genomics ✓ Disease burden and response kinetics ✓ MRD status ✓ Cytopenias/infection risk ✓ Tolerability and treatment goals The question may no longer be: “How long should Venetoclax be given?” Instead: “For which patient, at what disease state, and for how long?” Right patient. Right biology. Right duration. #AML #leusm #Venetoclax

@RahulBanerjeeMD @RascheLeo @RaabMarc @SurbhiSidanaMD @BMTjournal We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/rahul-b…

Kudos to @RascheLeo @RaabMarc et al for saying quiet part out loud. Given importance of bridging therapy (BT) to CAR-T outcomes in myeloma ( @SurbhiSidanaMD et al), should we consider extending BT prn to debulk further? Results of 🇩🇪 consensus panel, now in @BMTjournal: Yes!

@DrewMoghanaki We would like to inform you that your post has been published on OncoDaily. Thank you for sharing. oncodaily.com/voices/drew-mo…

Post SBRT image evaluation ambiguities are real and certainly an issue. It theoretically might undermines a patient’s outcome if mismanaged (unnecessary biopsies, etc). Although the theoretical harms associated with that maybe similar in frequency to postop complication rates after nephrectomy. Which is why I think we really need a RCT to confirm the benefit of surgery at this time in history to feel better about endorsing an operation. @_ShankarSiva